Introduction to the information for preventing and managing cardiovascular diseases such as ischemic heart disease, hypertension, and heart failure.
2013 prevention guidelines on obesity, cholesterol, risk assessment and lifestyle: obesity requires long-term professional management; lower overall heart attack and stroke risk, not just cholesterol; assessing risk of heart attack and stroke in more people; lifestyle recommendations for dietary patterns and exercise.
Life’s Simple 7: Avoiding being overweight or obese, eating a healthy diet, not smoking, being physically active, and keeping total cholesterol, blood pressure, and fasting glucose at goal level.
Eighth Joint National Committee (JNC 8) guideline for the management of high blood pressure (BP) in adults: There is strong evidence to support treating hypertensive persons aged 60 years or older to a BP goal of less than 150/90 mm Hg and hypertensive persons 30 through 59 years of age to a diastolic goal of less than 90 mm Hg; the panel recommends a BP of less than 140/90 mm Hg for other groups based on expert opinion. The same thresholds and goals are recommended for hypertensive adults with diabetes or nondiabetic chronic kidney disease (CKD) as for the general hypertensive population younger than 60 years.
Intestinal microbiota may contribute to the well-established link between high levels of red meat consumption and cardiovascular disease risk.
Meta-analysis of prospective cohort studies concluded: It is unlikely that caffeine consumption causes or contributes to atrial fibrillation. Habitual caffeine consumption may reduce atrial fibrillation risk.
ESC Exercise, Sports Guidelines for CVD: The European Society of Cardiology (ESC) has issued the first guidelines for exercise and sports participation in individuals with cardiovascular (CV) disease (CVD). Key messages: CV screening before participation in recreational and competitive sports is aimed at the detection of disorders associated with sudden cardiac death and has the potential to lower CV risk through disease-specific and individualized patient management. CV screening in adult and senior athletes should target the higher prevalence of atherosclerotic coronary artery disease (CAD) including an assessment of CVD risk factors and exercise stress test. Coronary artery calcium scoring may be performed in asymptomatic athletes with a moderate atherosclerotic risk profile. Healthy adults of all ages and individuals with known cardiac disease should exercise on most days, totaling at least 150 min/week of moderate-intensity exercise. Individuals with CAD, at low risk for exercise-induced adverse events, should be considered eligible for competitive or leisure sports activities, with few exceptions. Competitive sports are not recommended in individuals with CAD, at high risk of exercise-induced adverse events or those with residual ischemia, with the exception for individually low-intensity skill sports. Exercise programs in heart failure (HF) improve exercise tolerance and quality of life and have a modest effect on all-cause and HF-specific mortality, and all-cause hospitalization and HF-specific hospitalization. Asymptomatic individuals with mild valvular heart disease may participate in all sporting activities including competitive sports. A select group of asymptomatic individuals with moderate valve disease who have good functional capacity and no evidence of myocardial ischemia, complex arrhythmias, or hemodynamic compromise on a maximal exercise stress test may be considered for competitive sports after careful discussion with an expert cardiologist. Implementation of healthy lifestyle behaviors including sports participation decreases the risk of CV events and mortality in individuals with aortopathies. Individuals with acute myocarditis or pericarditis should abstain from all sports while active inflammation is present. Individuals with cardiomyopathy or resolved myocarditis or pericarditis, who wish to participate in regular sports, should undergo comprehensive evaluation, including an exercise test, to assess the risk of exercise-induced arrhythmias. Individuals who are genotype positive/phenotype negative or have a mild cardiomyopathy phenotype and absence of symptoms or any risk factors, may be able to participate in competitive sports. A notable exception is arrhythmogenic cardiomyopathy where high-intensity exercise and competitive sports should be discouraged. Managing sports participation in individuals with arrhythmogenic conditions is guided by three principles: (i) preventing life-threatening arrhythmias during exercise; (ii) symptom management to allow sports; and (iii) preventing sports-induced progression of the arrhythmogenic condition. In each case, these three basic questions need to be addressed. Pre-excitation should be excluded in all athletes with paroxysmal supraventricular tachycardia, and ablation of the accessory pathway is recommended if present. In individuals with premature ventricular contraction who want to engage in sports, underlying structural or familial arrhythmogenic conditions must be excluded, since sports activity may trigger more malignant arrhythmias if those underlying conditions are present. Athletes with electrical abnormalities of genetic origin, such as the inherited ion channelopathies, require assessment and shared decision making in which cardiogeneticists are involved, given the complex interplay of genotype, phenotype, potential modifiers, and exercise. Individuals with pacemakers should not be discouraged from participation in sport because of the device but need to tailor their sports participation according to the underlying disease. Participation in leisure-time and competitive sport in patients with an implantable cardioverter defibrillator may be considered, but requires shared and individualized decision making, based on a higher likelihood of appropriate and inappropriate shocks during sports, and the potential consequences of short episodes of loss of consciousness. Patients with congenital heart disease should be encouraged to exercise and should be given a personalized exercise prescription. Source: https://academic.oup.com/eurheartj/
From Past to Present: A Historical Overview and Modern Drug Therapy for High Blood Pressure
High blood pressure (BP) is one of medicine’s most common and preventable killers. The story of its management is a tidy way to see medicine move from observation to measurement to randomized trials and precision care — and to understand why today’s approach mixes lifestyle, home monitoring, and combinations of drugs.
Early observations and crude treatments (antiquity → 18th century)
People noticed irregular or strong pulses for millennia (Hippocratic and later writers describe pulse abnormalities), but BP as a measurable quantity didn’t exist. Treatments were empirical and often aggressive — bleeding, purges, and herbal concoctions aimed at balancing humors rather than lowering BP.
Measuring BP: the scientific breakthrough (18th → early 20th century)
In 1733 Stephen Hales made the first true physiological measurement of BP by inserting tubes into animal arteries — technically brilliant but not useful clinically. Practical clinical measurement arrived much later: Scipione Riva-Rocci introduced a cuff-based sphygmomanometer in 1896, and in 1905 Nikolai Korotkoff described the audible sounds used to determine systolic and diastolic BP. Those two innovations transformed high BP from a vague clinical impression into a reproducible number.
Recognition of high BP as disease (early → mid-20th century)
Once BP could be measured, epidemiologists and clinicians began to link high readings with stroke, heart failure, and kidney disease. For decades, however, many doctors debated whether to treat “mild” or “asymptomatic” high BP — the harm of sustained high BP had to be proven in trials.
The drug era and the first effective treatments (mid-20th century)
The mid-1900s brought the first classes of drugs that actually lowered BP reliably: centrally acting agents (e.g., methyldopa), reserpine, guanethidine, and later thiazide diuretics (chlorothiazide appeared in the late 1950s). Large randomized trials in the 1960s–1980s (for example, landmark trials run by the British Medical Research Council and U.S. VA cooperative groups) demonstrated that treating high BP — even “mild” forms — reduced strokes and heart attacks. This evidence moved treatment of high BP from optional to standard practice.
Expansion of drug classes and modern pharmacology (1960s → 1990s)
Therapeutics diversified: beta-blockers (propranolol and later generations), calcium-channel blockers (CCBs, e.g., verapamil, nifedipine), Angiotensin-converting-enzyme inhibitors (ACEi, captopril emerged from peptide research and entered clinical use around the early 1980s), and later angiotensin receptor blockers (ARBs, e.g., losartan in the 1990s). The trend was toward more effective, tolerable drugs and fixed-dose combinations — making control easier and side effects fewer.
Large trials, lifestyle evidence, and guideline development (1990s → 2010s)
Clinical trials and population studies refined who should be treated and how aggressively. The DASH diet trial (published in 1997) showed powerful BP lowering from diet alone (fruits, vegetables, low salt and saturated fat). By the 2000s and 2010s, consensus panels (the U.S. JNC reports, European and international guidelines) codified thresholds and stepwise treatment strategies. Evidence from trials such as SPRINT (published 2015) pushed the field to consider lower systolic targets for some high-risk patients, though target debates continue.
From office numbers to out-of-office care (2000s → present)
Recognition of white-coat and masked high BP led to widespread use of home BP monitoring and ambulatory 24-hour monitoring. These tools improved diagnosis and treatment decisions. Public-health moves — salt-reduction campaigns, promoting healthier food environments, and smoking cessation — also became central to population control of BP.
Newer approaches and future directions (2010s → now)
Precision medicine, risk-based treatment (treating based on overall cardiovascular risk rather than single BP numbers), and combination pills are now common. Device therapies (e.g., renal denervation) have been studied with mixed results but remain an area of active research. Digital health (apps, connected BP cuffs, telemonitoring) is increasingly used to improve adherence and remote titration of therapy. Equity and global access remain big challenges: many people worldwide still lack diagnosis or affordable medication.
Overview of the modern pharmacologic toolbox
Current first-line drug classes for most patients with uncomplicated high BP are:
β-blockers and alpha-blockers still have important indications (ischemic heart disease, heart failure, arrhythmias, specific secondary causes), but are no longer first-line for uncomplicated high BP in many guidelines because of comparative outcome data. These choices reflect large randomized trials and meta-analyses that compare outcomes (stroke, heart attack, heart failure, mortality), not just BP lowering alone. PubMed+1
Thiazide and thiazide-like diuretics — the classic backbone
Thiazide diuretics were among the first agents shown in large trials to reduce stroke and other cardiovascular (CV) events when used to treat high BP, and remain a mainstay — often in low-dose form or combined with other agents. The SHEP trial showed that treating isolated systolic high BP in the elderly with chlorthalidone reduced stroke and major CV events. PubMed
ALLHAT (2002) — one of the largest high BP outcome trials — compared chlorthalidone (a long-acting thiazide-like diuretic) with amlodipine and lisinopril in high-risk high BP patients. Overall, chlorthalidone performed as well or better for many outcomes (reduced heart-failure vs amlodipine; better stroke/CV outcomes vs lisinopril in some subgroups), which cemented thiazide-like diuretics as first-line options in many settings. PubMedJAMA Network
A 2022 NEJM study compared chlorthalidone with hydrochlorothiazide for CV outcomes; the results and interpretation added nuance about comparative effectiveness and safety (differences in potency, duration, electrolyte effects). Use/choice may depend on patient comorbidities and monitoring capacity. New England Journal of Medicine
Chlorthalidone or indapamide often favored where durable BP lowering is needed; monitor electrolytes and kidney function, especially in older adults or those on multiple agents.
Renin-angiotensin system blockers — ACEis and ARBs
ACEi: Landmark trials such as HOPE (ramipril) demonstrated reductions in myocardial infarction (MI), stroke, and CV death in high-risk patients, benefits that extend beyond BP lowering in many analyses. ACE inhibitors are recommended particularly when there is diabetes with albuminuria, chronic kidney disease (CKD), or heart failure. New England Journal of MedicinePubMed
ARBs: Trials such as LIFE (losartan vs atenolol, in patients with LVH) showed losartan provided superior stroke reduction and fewer adverse metabolic effects compared with atenolol. ARBs are used as an alternative in ACEi-intolerant patients (e.g., cough) and have favorable tolerability. PubMed+1
Combination strategies: ACEi/ARB + thiazide or CCB are common combinations — ACEi or ARB + CCB showed particular event reduction in some trials (see ACCOMPLISH below).
CCBs
CCBs (especially dihydropyridines like amlodipine) reduce stroke and other outcomes and are particularly effective in Black patients and older adults for lowering systolic BP. They are often used in combination regimens. The ALLHAT trial included an amlodipine arm and provided comparative safety/efficacy data versus chlorthalidone. PubMed
Key comparative combination trial — ACCOMPLISH
ACCOMPLISH (2008) randomized high-risk high BP patients to benazepril + amlodipine vs benazepril + hydrochlorothiazide and found the ACEi+CCB combination produced fewer CV events despite similar BP control. This trial influenced practice by highlighting that combination choice — not just BP number — can affect outcomes for high-risk patients. New England Journal of MedicinePubMed
Targets and treatment intensity — SPRINT and effect on therapeutic approach
SPRINT (2015; final analyses 2019) compared intensive systolic target (<120 mmHg) vs standard (<140 mmHg) in non-diabetic high-risk adults and found lower major CV events and lower all-cause mortality in the intensive group, at the cost of some increased adverse events (e.g., low BP, acute kidney injury). SPRINT changed thinking about targets and spurred individualized risk-based intensity decisions; it also emphasized the need for careful monitoring when intensifying therapy. New England Journal of Medicine+1
β-blockers — reappraisal from outcome data
Meta-analyses (notably Lindholm et al., Lancet 2005) found that β-blockers — particularly atenolol — were less effective than other classes for preventing stroke in primary high BP and may be inferior as first-line agents for uncomplicated high BP. β-blockers retain important roles for specific cardiac indications (post-MI, heart failure, rate control). PubMed
Special populations & elderly
Resistant high BP & devices
Interventional approaches such as renal sympathetic denervation showed early promise but the pivotal sham-controlled SYMPLICITY HTN-3 trial failed to show superiority vs sham at 6 months, highlighting the importance of rigorous randomized designs; more recent device studies are ongoing with improved techniques and patient selection. For now, device therapy is not routine and should be confined to clinical trials or specialist centers. New England Journal of MedicinePubMed
Summary
The management of high BP has evolved from ancient empirical remedies, such as bleeding and herbal treatments, to precise, evidence-based therapy grounded in major clinical trials. The introduction of the cuff sphygmomanometer by Riva-Rocci (1896) and Korotkoff’s sound method (1905) transformed high BP from a vague clinical impression into a measurable, treatable condition. Mid-20th-century trials established that pharmacologic treatment prevents stroke and heart disease, with thiazide diuretics leading the way. Subsequent decades brought ACE inhibitors, ARBs, CCBs, and strategic combinations such as ACEi+CCB, alongside refined treatment targets influenced by intensive-control results. While β-blockers have shifted to niche roles, lifestyle modification remains the foundation, and modern care emphasizes combination pills, out-of-office monitoring, and individualized targets. Collectively, these advances have turned high BP from a silent, often fatal condition into one of medicine’s most preventable causes of CV disease.
Source: revised from ChatGPT
A Brisk Historical Overview of Heart Failure Management
From foxglove to diuretics (1785–1960s). The modern story of heart failure (HF) starts with William Withering’s 1785 monograph describing digitalis (foxglove) for “dropsy,” a syndrome we now recognize as HF; digoxin remained a mainstay for symptom control for centuries. PubMe Project GutenbergNew England Journal of Medicine In the mid-20th century, oral thiazide diuretics arrived (chlorothiazide in 1957), followed by loop diuretics (furosemide, FDA-approved 1966), transforming decongestion in HF. PMCJAMA NetworkDrugs.com
The vasodilator and angiotensin-converting enzyme (ACE)-inhibitor era (1980s–early 1990s). Vasodilators were first to show survival benefits: V-HeFT I (1986) found hydralazine–isosorbide dinitrate (H-ISDN) reduced mortality vs placebo; V-HeFT II later showed enalapril outperformed H-ISDN. PubMed2 Minute Medicine Landmark ACE-inhibitor trials then defined disease-modifying therapy: CONSENSUS (1987) in severe HF and SOLVD-Treatment (1991) in ambulatory HF both reduced mortality with enalapril. New England Journal of Medicine+1
Neurohormonal blockade expands (late 1990s–2000s). Beta-blockers became foundational after MERIT-HF (metoprolol CR/XL), CIBIS-II (bisoprolol), and COPERNICUS (carvedilol) each showed mortality benefits in HF with Reduced Ejection Fraction (HFrEF). New England Journal of MedicineThe LancetPubMed Angiotensin receptor blockers (ARBs) provided alternatives/add-on therapy (Val-HeFT; CHARM programs). New England Journal of MedicinePubMed Aldosterone antagonists followed: RALES (spironolactone) reduced death in advanced HFrEF; EPHESUS (eplerenone) after MI with LV dysfunction, and EMPHASIS-HF in milder HFrEF extended the class’s reach. New England Journal of Medicine+2New England Journal of Medicine+2 For self-identified Black patients with HFrEF, A-HeFT (2004) re-established H-ISDN as mortality-reducing add-on therapy. New England Journal of Medicine
Devices and advanced therapies (2000s). Sudden-death prevention and resynchronization reshaped outcomes: MADIT-II showed implantable cardioverter-defibrillator (ICD) improved survival post-MI with low EF; COMPANION and CARE-HF proved cardiac resynchronization therapy (CRT, ± ICD) reduces death/hospitalization in wide-QRS HF. New England Journal of Medicine+2New England Journal of Medicine+2 For end-stage disease, transplantation (pioneered in 1967; later enabled by cyclosporine) and durable LVADs (REMATCH trial; continuous-flow HeartMate II) created viable long-term options. PMCNew England Journal of Medicine+2
The angiotensin receptor blocker and neprilysin inhibitor (ARNI) and sodium-glucose co-transporter 2 (SGLT2) inhibitor era (2014–present). PARADIGM-HF (2014) showed the ARNI sacubitril/valsartan superior to enalapril for CV death or HF hospitalization, ushering in “quadruple therapy.” New England Journal of Medicine SGLT2 inhibitors then proved powerful across the EF spectrum: DAPA-HF (2019) and EMPEROR-Reduced (2020) in HFrEF; EMPEROR-Preserved (2021) and DELIVER (2022) extending benefits to HF with preserved ejection fraction (HFpEF) and HF with mid-range ejection fraction (HFmrEF). New England Journal of Medicine+1The Lancet+1 Additional modern options include vericiguat after recent decompensation (VICTORIA), IV iron for iron deficiency (AFFIRM-AHF; IRONMAN), and the myotrope omecamtiv mecarbil (GALACTIC-HF).
Diagnosis and staging advances. The Framingham criteria (1971) standardized clinical diagnosis and epidemiology. New England Journal of Medicine Discovery of B-type natriuretic peptide (1988) and subsequent trials (e.g., Breathing Not Properly; NEJM BNP study) established BNP/NT-proBNP testing for diagnostic and prognostic use. NatureBlake WachterNew England Journal of Medicine
Current guidelines. Contemporary guidelines (AHA/ACC/HFSA 2022; ESC 2021/2023 update) recommend foundational quadruple therapy for HFrEF, with ARNI/ACEi/ARB + evidence-based β-blocker + mineralocorticoid receptor antagonists (MRA) + SGLT2 inhibitor, device therapy, iron repletion, and advanced therapies as appropriate—and emphasize prevention and staging from “at risk” through advanced HF. Recommendations for HFpEF (LVEF ≥ 50%) are less robust but evolving. AHAA JournalsHeart Failure Society of AmericaOxford Academic+1
Summary. The management of HF has progressed from symptom-relief with digitalis and diuretics to modern evidence-based, disease-modifying strategies. For HFrEF, contemporary guidelines recommend “quadruple therapy” with an ARNI (or ACEi/ARB), an evidence-based β-blocker, a mineralocorticoid receptor antagonist, and an SGLT2 inhibitor, with ICD/CRT devices, iron repletion, and advanced options for select patients; Guideline-directed medical therapy should be initiated or continued during hospitalization and maintained even if EF improves. For HFpEF, effective therapies were long limited to diuretics for congestion, but recent trials support SGLT2 inhibitors and possibly MRAs, ARBs, or ARNI. These strategies, codified in US and European guidelines, reflect the evolution from symptomatic care to comprehensive, outcome-driven management across the HF spectrum.
Source: Revised from ChatGPT
This website uses cookies.